Renalytix Plc (NASDAQ:RNLX) Short Interest Update

Renalytix Plc (NASDAQ:RNLX) was the target of a significant growth in short interest in March. As of March 15th, there was short interest totalling 894,600 shares, a growth of 78.7% from the February 29th total of 500,600 shares. Based on an average daily volume of 1,890,000 shares, the days-to-cover ratio is currently 0.5 days.

Renalytix Price Performance

Shares of RNLX traded down $0.08 during trading hours on Thursday, reaching $0.83. 379,921 shares of the stock traded hands, compared to its average volume of 1,996,581. Renalytix has a 52-week low of $0.24 and a 52-week high of $4.04. The company has a current ratio of 0.59, a quick ratio of 0.59 and a debt-to-equity ratio of 1.08. The company has a market cap of $41.54 million, a P/E ratio of -1.82 and a beta of 3.09. The company’s 50-day moving average price is $0.75 and its two-hundred day moving average price is $0.87.

Renalytix (NASDAQ:RNLX) last announced its quarterly earnings data on Wednesday, February 14th. The company reported ($0.09) EPS for the quarter, meeting the consensus estimate of ($0.09). Renalytix had a negative return on equity of 1,008.88% and a negative net margin of 1,736.47%. The business had revenue of $0.71 million for the quarter, compared to the consensus estimate of $0.70 million.

Institutional Investors Weigh In On Renalytix

A number of institutional investors have recently added to or reduced their stakes in RNLX. Tejara Capital Ltd purchased a new position in shares of Renalytix in the fourth quarter worth $757,000. Allspring Global Investments Holdings LLC bought a new stake in Renalytix in the 3rd quarter valued at $547,000. CI Private Wealth LLC purchased a new stake in Renalytix in the 4th quarter worth $352,000. Renaissance Technologies LLC bought a new position in shares of Renalytix during the 3rd quarter valued at about $161,000. Finally, Pinnacle Associates Ltd. grew its position in shares of Renalytix by 7.7% during the fourth quarter. Pinnacle Associates Ltd. now owns 846,534 shares of the company’s stock valued at $330,000 after purchasing an additional 60,572 shares in the last quarter. 9.92% of the stock is owned by hedge funds and other institutional investors.

About Renalytix

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score.